Growing demand for contract manufacturing services; concentrating on core competencies of pharmaceutical and biopharmaceutical companies; and increasing demand for biosimilars and generics are key factors driving the global CRO regulatory services for the generic and biosimilar drug market.

Increasing pollution in emerging economies has resulted in degradation of air quality which is one of the major reasons for increasing COPD and asthma prevalence amongst children and teenagers.

Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.

Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.